PHAR
NASDAQPharming Group N.V. ADS each representing 10
Pharming Group N.V. ADS each representing 10 (PHAR) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for PHAR, including 4 SEC filings, 3 press releases and news items and 2 earnings updates. The most recent was published Nov 11, 2026.
Financial highlights
Full financials- Revenue, FY2025
- $376.13M
- Revenue growth
- +26.6%
- Net income, FY2025
- $2.85M
- Net margin
- 0.8%
- Free cash flow, FY2025
- $53.96M
- Cash
- $145.31M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks30-12%
2026-05-172026-11-08
Mix1890d
- SEC Filings8(44%)
- Other7(39%)
- Earnings2(11%)
- Leadership1(6%)
Activity · 52 weeks5634 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRPharming to participate in fireside chat at Jefferies Global Healthcare Conference in LondonLeiden, the Netherlands, November 11, 2026: Pharming (NASDAQ:PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in London, United Kingdom, on November 16-19, 2026. Leverne Marsh, Interim Co-CEO & Chief Commercial Officer, and Kenneth Lynard, Interim Co-CEO & Chief Financial Officer, and Michael Levitan, VP Investor Relations and Capital Markets, will participate in a fireside chat Q&A session on Wednesday, November 18 at 9:30 a.m. GMT (10:30 a.m. CET / 4:30 a.m. EST). A live webcast and replay of the presentation will be made available in the "Events and presentations" and "Our news" sections of Pharming’s website. For more information about this co
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRMHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks another step in Pharming’s strategy to expand Joenja across age groups and international markets Leiden, the Netherlands, November 6, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved an extension of the marketing authorization of Joenja®, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to include c
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberThird quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectationsRUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025, reflecting demand stabilization and seasonal inventory increaseJoenja® (leniolisib) revenue increased by 58% to US$23.8 million, compared to third quarter 2025, reflecting strong U.S. and international demandTightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 millionOperating profit increased by 89% to US$29.9 million, compared to third quarter 2025Generated US$32.4 million in cash flow from operations in the quarter and
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming Group announces third quarter 2026 revenues above market expectationsThird quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter 2025Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 millionFull third quarter financial results and business update brought forward to October 27, 2026; conference call and webcast for analysts and investors to follow at 13:30 CET/08:30 EDT Leiden, the Netherlands, October 22, 2026: Pharming Group N.V. (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announces prelimin
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was well-tolerated, with benefits observed across multiple measures of immune dysregulation, including improvement in lymphoproliferation and positive trends in lung and liver disease markersAll participants who completed the study elected to continue receiving treatment in a long-term extension study Leiden, the Netherlands, October 14, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today presented positive topline data from its Phase II trial of leniol
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces CEO transitionLeiden, the Netherlands, September 29, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect. To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board has started a formal searc
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDSIf approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or moreDecision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kgPDUFA target action date of January 30, 2027 Leiden, the Netherlands, September 25, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, for children aged 4 years and olde
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026 Leiden, the Netherlands, September 22, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling has been accepted at the 22nd Biennial Meeting
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be available in October Leiden, the Netherlands, September 11, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years weighing at leas
- PRPharming Group to participate in September investor conferencesLeiden, the Netherlands, September 9, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced that its management will participate in the following investor conferences in the month of September: H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in the "Events and presentations" and "Our news" sections of Pharming’s website. Morgan Stanley 24th Annual Global Healthcare Conference, New York, September 15, 2026 For more information about these conferences, or to schedule
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderLaunch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan Leiden, the Netherlands, August 13, 2026: Pharming Group (NASDAQ:PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 years and older, following its inclusion on the Japan National Health Insurance (NHI) drug price list. With this launch, Japan is now the first market where Joenja is commercially available for children aged 4 to 11. "This launch is an important milest
- PRPharming Group to participate in Canaccord Genuity 46th Annual Growth ConferenceLeiden, the Netherlands, August 4, 2026: Pharming Group N.V. (NASDAQ:PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP Investor Relations and Capital Markets, will participate in a Fireside Chat Q&A session on Wednesday, August 12 at 10:00 EDT/16:00 CEST. For more information about the conference, or to schedule a one-on-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Canaccord Genuity representative. About Pharming Group N.V.Pharming Group N.V. (NASDAQ:PHAR) is a global biopharmaceutical company dedicated to tr
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic useFor investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the second quarter 2025 and a 24% increase compared to the first quarter 2026, with active patient base 93% of year-ago and strong new patient enrollmentsJoenja® revenue was US$17.9 million, a 40% increase compared to the second quarter 2025, reflecting continued strong U.S. and international growth, with first European launch in Germany after quarter-endSecond quarter operating profit amounted to US$1.3 million compared to US$10.8 million in the second quarter 2025, impacted by manuf
- PRPharming Group to report second quarter and first half 2026 financial results and provide business update on July 30Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and provide a business update on Thursday, July 30, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CEST/07:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BId285845cff504c39931913d279f646ea Once registered, dial-in information and a unique PIN will be provided, allowi
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
PHAR FAQ
10 questionsWhat does Pharming Group N.V. ADS each representing 10 do?
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase...What is the latest news on PHAR?
In the last 30 days Quantisnow tracked 9 wire items for PHAR: 4 SEC filings, 3 press releases and news items and 2 earnings updates. The most recent was published on November 11, 2026.What is PHAR revenue?
Pharming Group N.V. ADS each representing 10 (PHAR) reported $376.13M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 26.6% from the year before.Is PHAR profitable?
Yes. Pharming Group N.V. ADS each representing 10 earned $2.85M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 0.8%.How much cash and debt does PHAR have?
Pharming Group N.V. ADS each representing 10 reported $145.31M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PHAR stock trade?
Pharming Group N.V. ADS each representing 10 (PHAR) is listed on NASDAQ.What sector and industry is PHAR in?
Pharming Group N.V. ADS each representing 10 operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PHAR?
Pharming Group N.V. ADS each representing 10 has had 2 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $37.00 price target on 2026-04-10. Recent price targets range from $14.00 to $37.00.What companies are similar to PHAR?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare PHAR side-by-side with any of them on Quantisnow.How can I track PHAR on Quantisnow?
Quantisnow aggregates Pharming Group N.V. ADS each representing 10's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHAR to receive live email and push alerts on every new disclosure.